Sanofi, busy with cost-savings campaign, restructures US commercial vaccine group

During a busy period of overhaul at Sanofi, the company is restructuring its U.S. vaccine commercial group.

The company is "implementing a streamlined strategic sales structure" as the U.S. vaccine market continues to evolve, a spokesperson said. The move is "aimed at optimizing our commercial structure for greater efficiency and effectiveness," he added.